A Phase 1 Dose Escalation Study of TTI-237 Administered Intravenously Every 3 Weeks in Subjects With Advanced Malignant Solid Tumors
Phase of Trial: Phase I
Latest Information Update: 23 Mar 2007
At a glance
- Drugs Cevipabulin (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- 09 Sep 2005 New trial record.